Clinuvel Pharmaceuticals Ltd has released a press release.
US FDA Update
Filed with ASX ·
On 6ix: 6ix.com/news/us-fda-update
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL completes SCENESSE FDA Filing
- NICE maintains position not to recommend SCENESSE
- CLINUVEL Regulatory Update
- Clinuvel to take 100% ownership of vallaurix joint venture
- CLINUVEL hosts European EPP Expert Meeting
Later from Clinuvel Pharmaceuticals
- S&P DJI Announces September 2018 Quarterly Rebalance
- Appeal Upheld Against NICE Recommendation in England
- CUV103 Singaporean Phase II vitiligo study results
- US FDA sets PDUFA date for SCENESSE
- US FDA extends PDUFA date for SCENESSE
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals